<!DOCTYPE html>

<html>

<head>

<meta charset="utf-8" />
<meta name="generator" content="pandoc" />
<meta http-equiv="X-UA-Compatible" content="IE=EDGE" />



<meta name="date" content="2026-02-13" />

<title>EMCURE</title>

<script src="rmdlib/header-attrs-2.30/header-attrs.js"></script>
<script src="rmdlib/jquery-3.6.0/jquery-3.6.0.min.js"></script>
<meta name="viewport" content="width=device-width, initial-scale=1" />
<link href="rmdlib/bootstrap-3.3.5/css/flatly.min.css" rel="stylesheet" />
<script src="rmdlib/bootstrap-3.3.5/js/bootstrap.min.js"></script>
<script src="rmdlib/bootstrap-3.3.5/shim/html5shiv.min.js"></script>
<script src="rmdlib/bootstrap-3.3.5/shim/respond.min.js"></script>
<style>h1 {font-size: 34px;}
       h1.title {font-size: 38px;}
       h2 {font-size: 30px;}
       h3 {font-size: 24px;}
       h4 {font-size: 18px;}
       h5 {font-size: 16px;}
       h6 {font-size: 12px;}
       code {color: inherit; background-color: rgba(0, 0, 0, 0.04);}
       pre:not([class]) { background-color: white }</style>
<script src="rmdlib/navigation-1.1/tabsets.js"></script>
<script src="rmdlib/accessible-code-block-0.0.1/empty-anchor.js"></script>
<link href="rmdlib/font-awesome-6.4.0/css/all.min.css" rel="stylesheet" />
<link href="rmdlib/font-awesome-6.4.0/css/v4-shims.min.css" rel="stylesheet" />
<meta name="description" content="Indian equities analysis, margin reports, risk, etc..." />
<meta property="og:image" content="https://avatars3.githubusercontent.com/u/21966469?s=400&v=4" />

<style type="text/css">
  code{white-space: pre-wrap;}
  span.smallcaps{font-variant: small-caps;}
  span.underline{text-decoration: underline;}
  div.column{display: inline-block; vertical-align: top; width: 50%;}
  div.hanging-indent{margin-left: 1.5em; text-indent: -1.5em;}
  ul.task-list{list-style: none;}
    </style>










<style type = "text/css">
.main-container {
  max-width: 940px;
  margin-left: auto;
  margin-right: auto;
}
img {
  max-width:100%;
}
.tabbed-pane {
  padding-top: 12px;
}
.html-widget {
  margin-bottom: 20px;
}
button.code-folding-btn:focus {
  outline: none;
}
summary {
  display: list-item;
}
details > summary > p:only-child {
  display: inline;
}
pre code {
  padding: 0;
}
</style>


<style type="text/css">
.dropdown-submenu {
  position: relative;
}
.dropdown-submenu>.dropdown-menu {
  top: 0;
  left: 100%;
  margin-top: -6px;
  margin-left: -1px;
  border-radius: 0 6px 6px 6px;
}
.dropdown-submenu:hover>.dropdown-menu {
  display: block;
}
.dropdown-submenu>a:after {
  display: block;
  content: " ";
  float: right;
  width: 0;
  height: 0;
  border-color: transparent;
  border-style: solid;
  border-width: 5px 0 5px 5px;
  border-left-color: #cccccc;
  margin-top: 5px;
  margin-right: -10px;
}
.dropdown-submenu:hover>a:after {
  border-left-color: #adb5bd;
}
.dropdown-submenu.pull-left {
  float: none;
}
.dropdown-submenu.pull-left>.dropdown-menu {
  left: -100%;
  margin-left: 10px;
  border-radius: 6px 0 6px 6px;
}
</style>

<script type="text/javascript">
// manage active state of menu based on current page
$(document).ready(function () {
  // active menu anchor
  href = window.location.pathname
  href = href.substr(href.lastIndexOf('/') + 1)
  if (href === "")
    href = "index.html";
  var menuAnchor = $('a[href="' + href + '"]');

  // mark the anchor link active (and if it's in a dropdown, also mark that active)
  var dropdown = menuAnchor.closest('li.dropdown');
  if (window.bootstrap) { // Bootstrap 4+
    menuAnchor.addClass('active');
    dropdown.find('> .dropdown-toggle').addClass('active');
  } else { // Bootstrap 3
    menuAnchor.parent().addClass('active');
    dropdown.addClass('active');
  }

  // Navbar adjustments
  var navHeight = $(".navbar").first().height() + 15;
  var style = document.createElement('style');
  var pt = "padding-top: " + navHeight + "px; ";
  var mt = "margin-top: -" + navHeight + "px; ";
  var css = "";
  // offset scroll position for anchor links (for fixed navbar)
  for (var i = 1; i <= 6; i++) {
    css += ".section h" + i + "{ " + pt + mt + "}\n";
  }
  style.innerHTML = "body {" + pt + "padding-bottom: 40px; }\n" + css;
  document.head.appendChild(style);
});
</script>

<!-- tabsets -->

<style type="text/css">
.tabset-dropdown > .nav-tabs {
  display: inline-table;
  max-height: 500px;
  min-height: 44px;
  overflow-y: auto;
  border: 1px solid #ddd;
  border-radius: 4px;
}

.tabset-dropdown > .nav-tabs > li.active:before, .tabset-dropdown > .nav-tabs.nav-tabs-open:before {
  content: "\e259";
  font-family: 'Glyphicons Halflings';
  display: inline-block;
  padding: 10px;
  border-right: 1px solid #ddd;
}

.tabset-dropdown > .nav-tabs.nav-tabs-open > li.active:before {
  content: "\e258";
  font-family: 'Glyphicons Halflings';
  border: none;
}

.tabset-dropdown > .nav-tabs > li.active {
  display: block;
}

.tabset-dropdown > .nav-tabs > li > a,
.tabset-dropdown > .nav-tabs > li > a:focus,
.tabset-dropdown > .nav-tabs > li > a:hover {
  border: none;
  display: inline-block;
  border-radius: 4px;
  background-color: transparent;
}

.tabset-dropdown > .nav-tabs.nav-tabs-open > li {
  display: block;
  float: none;
}

.tabset-dropdown > .nav-tabs > li {
  display: none;
}
</style>

<!-- code folding -->




</head>

<body>


<div class="container-fluid main-container">




<div class="navbar navbar-inverse  navbar-fixed-top" role="navigation">
  <div class="container">
    <div class="navbar-header">
      <button type="button" class="navbar-toggle collapsed" data-toggle="collapse" data-bs-toggle="collapse" data-target="#navbar" data-bs-target="#navbar">
        <span class="icon-bar"></span>
        <span class="icon-bar"></span>
        <span class="icon-bar"></span>
      </button>
      <a class="navbar-brand" href="index.html">StockViz</a>
    </div>
    <div id="navbar" class="navbar-collapse collapse">
      <ul class="nav navbar-nav">
        <li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-globe"></span>
     
    Macro
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports01/macro/rp-bnd.html">Fixed Income</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/macro/rp-cur.html">Currencies</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/macro/rp-cmdy.html">Commodities</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-arrows-v"></span>
     
    52w H&amp;L
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports01/eq/52wk-IN.html">India</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/eq/52wk-US.html">US</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-rocket"></span>
     
    ATH
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports01/eq/ath-IN.html">India</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/eq/ath-US.html">US</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-magnet"></span>
     
    Drawdowns
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports01/eq/drawdowns-IN.html">India</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/eq/drawdowns-US.html">US</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-train"></span>
     
    Streaks
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports01/eq/streaks-IN.html">India</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/eq/streaks-US.html">US</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-hand-pointer-o"></span>
     
    Indian Indices
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports01/index/rp-risk.html">Performance Metrics</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/index/rp-IN.html">Index Changes</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/index/rp-MKT-CAP.html">Classification Changes</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/index/rp-industry.html">Industry Metrics</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/index/rp-syn.html">Synthetic Indices</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/index/rp-vol-NIFTY.html">NIFTY Volatility</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/index/rp-valuations.html">Valuations</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/eq/results-IN.html">Result Dates</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports02/eq-in/rp-margin.html">Margin Report</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-shopping-bag"></span>
     
    Funds
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports03/mf/rp-IN.html">Indian Mutual Funds</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports03/pms/rp-IN.html">Indian PMS</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports02/etf-us/rp-risk.html">US ETFs</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports02/etf-us/rp-sector.html">US Sector ETFs</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports02/etf-us/rp-country.html">Country $ ETFs</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-percent"></span>
     
    Fama-French
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports02/etf-us/rp-fama-french-industry.html">Industry</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports02/etf-us/rp-fama-french-factors.html">Factors</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports02/etf-us/rp-fama-french-regression.html">Regressions</a>
    </li>
  </ul>
</li>
      </ul>
      <ul class="nav navbar-nav navbar-right">
        <li>
  <a href="https://stockviz.biz">
    <span class="fa fa-home"></span>
     
  </a>
</li>
<li>
  <a href="https://stockviz.substack.com">
    <span class="fa fa-envelope-o"></span>
     
  </a>
</li>
      </ul>
    </div><!--/.nav-collapse -->
  </div><!--/.container -->
</div><!--/.navbar -->

<div id="header">



<h1 class="title toc-ignore">EMCURE</h1>
<h3 class="subtitle">Equity Metrics</h3>
<h4 class="date">February 13, 2026</h4>

</div>


<div id="emcure-pharmaceuticals-limited" class="section level1">
<h1>Emcure Pharmaceuticals Limited</h1>
<p><a href="/reports01/index/industry/rp-Pharmaceuticals.html">Pharmaceuticals</a></p>
<div id="annual-returns" class="section level2">
<h2>Annual Returns</h2>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.EMCURE.fan.png" /></p>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.EMCURE.annret.png" /></p>
</div>
<div id="cumulative-returns-and-drawdowns" class="section level2">
<h2>Cumulative Returns and Drawdowns</h2>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.EMCURE.cumret.png" /></p>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.EMCURE.sma.cumret.png" /></p>
<p><br><br></p>
</div>
<div id="fundamentals" class="section level2">
<h2>Fundamentals</h2>
<p><br />
</p>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.EMCURE.eps.png" /></p>
<p><br><br></p>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.EMCURE.RevenueFromOperations.png" /></p>
<p><br><br></p>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.EMCURE.ebit.png" /></p>
<p><br><br></p>
</div>
<div id="ownership" class="section level2">
<h2>Ownership</h2>
<p><br />
</p>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.EMCURE.ownership.png" /></p>
<p><br><br></p>
</div>
<div id="margined" class="section level2">
<h2>Margined</h2>
<p><br />
</p>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.EMCURE.mtf.png" /></p>
<p><br><br></p>
<p><br />
</p>
</div>
<div id="ai-summary" class="section level2">
<h2>AI Summary</h2>
<p><em>asof: 2025-12-03 </em></p>
<div id="emcure-pharmaceuticals-limited-emcure-analysis" class="section level3">
<h3>Emcure Pharmaceuticals Limited (EMCURE) Analysis</h3>
<p>Emcure Pharmaceuticals (EMCURE), a leading Indian pharma player ranked ~#13 in domestic sales (MAT Sep’25 IQVIA), demonstrates robust growth momentum driven by domestic leadership in gynae/cardio, international expansion in complex generics/biosimilars, and strategic partnerships. FY25 revenue: ₹7,896 Cr (46% domestic). H1FY26 showed 14.5% YoY revenue growth to ₹4,370 Cr and 31% PAT growth to ₹466 Cr. Below is a structured analysis based on the provided filings (Q2FY26 results, investor presentation, regulatory disclosures, partnerships).</p>
<div id="tailwinds-positive-catalysts" class="section level6">
<h6><strong>Tailwinds (Positive Catalysts)</strong></h6>
<table>
<colgroup>
<col width="32%" />
<col width="36%" />
<col width="32%" />
</colgroup>
<thead>
<tr class="header">
<th>Factor</th>
<th>Details</th>
<th>Impact</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td><strong>Strong Financial Momentum</strong></td>
<td>Q2FY26: Revenue +13% YoY (₹2,270 Cr), PAT +25% (₹251 Cr, 11% margins). H1FY26 EBITDA margins ~19% (expansion via productivity/utilization). Domestic +11%, Intl +16%.</td>
<td>Supports re-rating; ROCE delivery.</td>
</tr>
<tr class="even">
<td><strong>Domestic Augmentation</strong></td>
<td>#2 in gynae; 11/31 brands &gt;₹50-100 Cr; PPM improved to 5.7. In-licensing (Sanofi Amaryl/Cetapin, Novo Poviztra® semaglutide for obesity). Zuventus 100% acquired (₹725 Cr). New areas: OTC (Arth/Galact), Derm, Super-specialty.</td>
<td>50% revenue from complex products; obesity market entry (₹12 Bn TAM, 10% CAGR).</td>
</tr>
<tr class="odd">
<td><strong>International Scale-Up</strong></td>
<td>30% revenue share from complex (iron/chiral/injectables). Europe +23% (Liposomal Ampho B first generic, Manx acquisition doubles UK portfolio). Canada +18% (top-10 generics, CAD 236 Mn size). RoW inflection (non-ARV). 70+ countries.</td>
<td>~19% revenue from EU/CA/RoW; 900+ launches.</td>
</tr>
<tr class="even">
<td><strong>Pipeline &amp; Innovation</strong></td>
<td>50+ global filings (next 24M: Semaglutide, Bevacizumab, Lenacapavir, Ferric CarboxyMaltose, ADCs). Biologics/NDDS/LAI focus. US FDA clean inspection (Oct’25).</td>
<td>Differentiated products drive mid-teens growth &gt; industry.</td>
</tr>
<tr class="odd">
<td><strong>Strategic Moves</strong></td>
<td>Novo Nordisk exclusive distribution (first Indian for GLP-1 obesity drug). M&amp;A (Zuventus, Manx). Experienced leadership hires (ex-Sun/Ranbaxy).</td>
<td>Early mover in obesity; portfolio doubling.</td>
</tr>
</tbody>
</table>
</div>
<div id="headwinds-challenges" class="section level6">
<h6><strong>Headwinds (Challenges)</strong></h6>
<table>
<colgroup>
<col width="32%" />
<col width="36%" />
<col width="32%" />
</colgroup>
<thead>
<tr class="header">
<th>Factor</th>
<th>Details</th>
<th>Impact</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td><strong>Regulatory Scrutiny</strong></td>
<td>GST search/seizure (Nov 24-26, 2025) at Mumbai offices; full cooperation, no adverse findings yet.</td>
<td>Potential penalties/tax demands; sentiment drag (no material financial impact stated).</td>
</tr>
<tr class="even">
<td><strong>Debt &amp; Costs</strong></td>
<td>Borrowings up sharply (Sep’25: ₹13,441 Mn vs ₹7,317 Mn Mar’25). Finance costs ₹593 Mn H1FY26. Exceptional items (₹35 Mn legal settlement).</td>
<td>Interest burden; leverage risk amid capex (CWIP ₹1,436 Mn).</td>
</tr>
<tr class="odd">
<td><strong>Margin Pressures</strong></td>
<td>Employee costs high (₹778 Cr H1); forex gains volatile (net gain ₹492 Mn H1). Inventory build-up (₹23,046 Mn).</td>
<td>EBITDA stable but scaling volumes key.</td>
</tr>
<tr class="even">
<td><strong>Market Dynamics</strong></td>
<td>Domestic chronic share 28% (MAT Sep’25); generic pricing in Canada/EU.</td>
<td>Competition in gynae/obesity entry.</td>
</tr>
</tbody>
</table>
</div>
<div id="growth-prospects" class="section level6">
<h6><strong>Growth Prospects</strong></h6>
<ul>
<li><strong>Short-Term (12-18M)</strong>: Mid-high teens revenue growth (faster than industry). Domestic boosted by Poviztra® launch (obesity TAM huge: 254 Mn obese in India), 5 key launches, in-licensing synergies. Intl: Canada pipeline (8 first generics, TAM CAD 3 Bn), Europe injectables (TAM USD 1 Bn), RoW non-ARV ramp.</li>
<li><strong>Medium-Term (2-3Y)</strong>: 20%+ complex product share; biologics/ADC scale-up. Target: Domestic top-10, Intl 54% revenue. EBITDA margins to 20%+ via leverage.</li>
<li><strong>Catalysts</strong>: Earnings calls/investor meets (Dec’25), pipeline milestones, M&amp;A. FY26E guidance implicit: 15%+ growth.</li>
<li><strong>Valuation Context</strong>: Post-IPO delivery (revenue +18% FY25, PAT +30% last 6Q).</li>
</ul>
</div>
<div id="key-risks" class="section level6">
<h6><strong>Key Risks</strong></h6>
<table>
<colgroup>
<col width="41%" />
<col width="25%" />
<col width="33%" />
</colgroup>
<thead>
<tr class="header">
<th>Risk Category</th>
<th>Details</th>
<th>Mitigation</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td><strong>Regulatory</strong></td>
<td>GST probe outcome; US FDA/EU inspections; pricing reforms (Canada generics down 4.8% CAGR).</td>
<td>Clean track record; compliance focus.</td>
</tr>
<tr class="even">
<td><strong>Financial/Leverage</strong></td>
<td>Debt rise for acquisitions/capex; forex volatility (30% Intl exposure).</td>
<td>Cash generation strong (H1 op. cash ₹1,387 Mn standalone).</td>
</tr>
<tr class="odd">
<td><strong>Execution</strong></td>
<td>Pipeline delays (R&amp;D intensive); integration (Zuventus/Manx). Competition in obesity/generics.</td>
<td>In-house R&amp;D + partnerships; 14 subsidiaries stable.</td>
</tr>
<tr class="even">
<td><strong>Macro/External</strong></td>
<td>Supply chain (API imports); US$ fluctuations; US recession impacting RoW.</td>
<td>Diversified geographies; 50% complex margins buffer.</td>
</tr>
<tr class="odd">
<td><strong>Legal/Other</strong></td>
<td>Ongoing settlements (Canada pricing, disputes); NCI (2-3% equity).</td>
<td>One-offs; full Zuventus control reduces.</td>
</tr>
</tbody>
</table>
</div>
<div id="overall-summary" class="section level6">
<h6><strong>Overall Summary</strong></h6>
<p><strong>Bull Case</strong>: Tailwinds dominate with 15%+ sustainable growth, margin expansion (PAT 11%+), and obesity/injectables as game-changers. Novo partnership positions as anti-diabetes/obesity leader. Target: Top-10 domestic, 20% EBITDA. <strong>Bear Case</strong>: GST escalation or debt strain could cap multiples. <strong>Recommendation</strong>: Positive outlook (Buy/Accumulate); monitor GST updates. Trading at ~30-35x FY26E EPS (peer avg 25-40x). Strong execution post-IPO underscores resilience.</p>
<p><em>Analysis based solely on provided documents (as of Nov-Dec 2025). Not investment advice.</em></p>
</div>
</div>
</div>
</div>

&nbsp;
&nbsp;
<hr />
<p style="text-align: center;">Copyright &copy; 2023 SAS Data Analytics Pvt. Ltd. All rights reserved.</p>
<p style="text-align: center;"><a href="https://github.com/stockviz/reports/issues">&#x1F41E;</a></p>



</div>

<script>

// add bootstrap table styles to pandoc tables
function bootstrapStylePandocTables() {
  $('tr.odd').parent('tbody').parent('table').addClass('table table-condensed');
}
$(document).ready(function () {
  bootstrapStylePandocTables();
});


</script>

<!-- tabsets -->

<script>
$(document).ready(function () {
  window.buildTabsets("TOC");
});

$(document).ready(function () {
  $('.tabset-dropdown > .nav-tabs > li').click(function () {
    $(this).parent().toggleClass('nav-tabs-open');
  });
});
</script>

<!-- code folding -->


<!-- dynamically load mathjax for compatibility with self-contained -->
<script>
  (function () {
    var script = document.createElement("script");
    script.type = "text/javascript";
    script.src  = "https://mathjax.rstudio.com/latest/MathJax.js?config=TeX-AMS-MML_HTMLorMML";
    document.getElementsByTagName("head")[0].appendChild(script);
  })();
</script>

</body>
</html>
